Filing Details
- Accession Number:
- 0001209191-22-036137
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-06-10 19:51:29
- Reporting Period:
- 2022-06-08
- Accepted Time:
- 2022-06-10 19:51:29
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1808865 | Iteos Therapeutics Inc. | ITOS | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1457477 | David Hallal | C/O Iteos Therapeutics, Inc. 321 Arsenal Street Watertown MA 02472 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-06-08 | 5,968 | $4.23 | 5,968 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-06-08 | 5,968 | $20.39 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2022-06-08 | 11,899 | $2.95 | 11,899 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-06-08 | 11,899 | $20.39 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2022-06-08 | 10,577 | $4.23 | 10,577 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-06-08 | 10,577 | $19.86 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2022-06-09 | 1,171 | $4.23 | 1,171 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-06-09 | 1,171 | $19.51 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2022-06-08 | 5,968 | $0.00 | 5,968 | $4.23 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2022-06-08 | 11,899 | $0.00 | 11,899 | $2.95 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2022-06-08 | 10,577 | $0.00 | 10,577 | $4.23 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2022-06-09 | 1,171 | $0.00 | 1,171 | $4.23 |
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2022-06-09 | 17,538 | $0.00 | 17,538 | $18.78 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 157,908 | 2030-05-01 | No | 4 | M | Direct | |
| 25,140 | 2029-12-04 | No | 4 | M | Direct | |
| 147,331 | 2030-05-01 | No | 4 | M | Direct | |
| 146,160 | 2030-05-01 | No | 4 | M | Direct | |
| 17,538 | 2032-06-09 | No | 4 | A | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.1 to $20.84, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.75 to $20.12, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.37 to $19.62, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- One-fourth of the shares subject to the stock option vested on the one-year anniversary of the vesting commencement date. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis following the one-year anniversary of the vesting commencement date, subject to the reporting person continuous service relationship with the Issuer through each applicable vesting date.
- This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 9, 2023 or (b) the next annual meeting of the Issuer's stockholders.
Billionaire Hedge Funds
